ECU
AXSM icon

Eisler Capital (US)’s Axsome Therapeutics AXSM Stock Holding History

Eisler Capital (US)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,285
Closed -$828K – 492
2024
Q2 		$828K Buy
10,285
+1,239
+14% +$91.7K 0.01% 495
2024
Q1 		$722K Buy
+9,046
New +$759K 0.02% 411

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eisler Capital (US)'s AXSM Position: Q3 2024 in Review

Eisler Capital (US) sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 10,285 shares — an estimated $828K sold.

Eisler Capital (US) first reported a position in AXSM in Q1 2024 and held it in 2 quarters. The position peaked at $828K in Q2 2024. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Eisler Capital (US) reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 10,285 Axsome Therapeutics shares in Q3 2024, an estimated $828K.
  • Eisler Capital (US) first reported a position in Axsome Therapeutics in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s Axsome Therapeutics position peaked at $828K in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.